JTCS KCI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Friedhelm Beyersdorf
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Doenst, T.
Right arrow Articles by Beyersdorf, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doenst, T.
Right arrow Articles by Beyersdorf, F.
Related Collections
Right arrow Coronary disease
Right arrow Myocardial protection

J Thorac Cardiovasc Surg 2001;121:1221-1222
© 2001 The American Association for Thoracic Surgery

Letters to the Editor

Insulin cardioplegia for elective coronary bypass surgery

Torsten Doenst, MD, Benjamin E. Ayres, BSc, Friedhelm Beyersdorf, MD

Department of Cardiovascular Surgery
University of Freiburg
Freiburg I Br, Germany

To the Editor:

A recent article by Rao and associatesGo 1 reported an improvement in postoperative hemodynamic parameters in a group of patients who received insulin-enhanced cardioplegic solution during coronary artery bypass grafting. The authors attributed their observations to insulin promoting aerobic metabolism and suggested pyruvate dehydrogenase (PDH) activation . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2001 by The American Association for Thoracic Surgery.